Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | CA7 | P43166 | 1/20 | 0.55 |
| ▸ | CTSK | P43235 | 3/20 | 0.46 |
| ▸ | CTSL | P07711 | 2/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | CTSS | P25774 | 1/20 | 0.46 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.44 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.44 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.44 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.44 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.44 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19618687 | 1.00 | CA1 (0.55) | CA1CA2CA7CTSKCTSL | |
| SCHEMBL10724727 | 1.00 | CA1 (0.55) | CA1CA2CA7CTSKCTSL | |
| SCHEMBL5564464 | 1.00 | CA1 (0.55) | CA1CA2CA7CTSKCTSL | |
| SCHEMBL10724721 | 1.00 | CA1 (0.55) | CA1CA2CA7CTSKCTSL | |
| SCHEMBL8446912 | 0.88 | CA1 (0.53) | CA1CA2CA7CTSKCTSL | |
| SCHEMBL14385267 | 0.88 | CA1 (0.53) | CA1CA2CA7CTSKCTSL | |
| SCHEMBL13078313 | 0.88 | CA1 (0.53) | CA1CA2CA7CTSKCTSL | |
| SCHEMBL5496417 | 0.87 | CA1 (0.48) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL3893779 | 0.86 | CA1 (0.46) | CA1CA2CA7CTSKCTSL | |
| SCHEMBL7320189 | 0.86 | CA1 (0.57) | CA1CA2CA7CTSKCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11786504-B2 | Taxane analogs for the treatment of brain cancer | TAPESTRY PHARMACEUTICALS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11220512-B2 | Biologically active taxane analogs and methods of treatment by oral administration | TAPESTRY PHARMACEUTICALS, INC. (US) | 2022-01-11 | — | — | US | disclosed |
| US-20210401797-A1 | Taxane Analogs for the Treatment of Brain Cancer | TAPESTRY PHARMACEUTICALS, INC. (US) | 2021-12-30 | — | — | US | disclosed |
| US-20200347076-A1 | Biologically Active Taxane Analogs and Methods of Treatment by Oral Administration | TAPESTRY PHARMACEUTICALS INC (US) | 2020-11-05 | — | — | US | disclosed |
| US-10745408-B2 | Biologically active taxane analogs and methods of treatment by oral administration | TAPESTRY PHARMACEUTICALS, INC. (US) | 2020-08-18 | — | — | US | disclosed |
| US-10450323-B2 | Biologically active taxane analogs and methods of treatment by oral administration | TAPESTRY PHARMACEUTICALS, INC. (US) | 2019-10-22 | — | — | US | disclosed |
| US-20180105535-A1 | Biologically Active Taxane Analogs and Methods of Treatment by Oral Administration | TAPESTRY PHARMACEUTICALS, INC. | 2018-04-19 | — | — | US | disclosed |
| US-9802951-B2 | Biologically active taxane analogs and methods of treatment by oral administration | TAPESTRY PHARMACEUTICALS, INC. (US) | 2017-10-31 | — | — | US | disclosed |
| EP-1498411-B9 | DIKETOHYDRAZINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2013-12-04 | — | — | EP | disclosed |
| EP-1498411-B1 | DIKETOHYDRAZINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-20070004642-A1 | Oxadiazole derivatives and drugs containing these derivatives as the active ingredient | ONO PHARMACEUTICAL CO., LTD. | 2007-01-04 | — | — | US | disclosed |
| US-20070004642-A1 | Oxadiazole derivatives and drugs containing these derivatives as the active ingredient | ONO PHARMACEUTICAL CO., LTD. | 2007-01-04 | — | — | US | disclosed |
| US-7144901-B2 | Oxadiazole derivatives and drugs containing these derivatives as the active ingredient | ONO PHARMACEUTICAL CO.,LTD. (JP) | 2006-12-05 | — | — | US | disclosed |
| US-20060111303-A1 | Diketohydrazine derivative compounds and drugs contaiing the compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-05-25 | — | — | US | disclosed |
| EP-1498411-A1 | DIKETOHYDRAZINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-01-19 | — | — | EP | disclosed |
| US-6797720-B2 | 1,3,4-oxadiazoline derivative and an agent comprising its derivative as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-09-28 | — | — | US | disclosed |
| US-20030166574-A1 | 1,3,4-Oxadiazoline derivatives and drugs containing these derivatives as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-09-04 | — | — | US | disclosed |
| US-20030166573-A1 | Such as (2S)-N-((2S)-4-methyl-1-(5-(1-methylethylthio)1,3,4-oxadiazol-2-yl)-1-oxo-2 -pentyl)-2-benzyloxycarbonylamino-4-methylpentanamide for inhibition of cysteine proteases; antiinflammatory agents | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-09-04 | — | — | US | disclosed |
| EP-1234820-A1 | OXADIAZOLE DERIVATIVES AND DRUGS CONTAINING THESE DERIVATIVES AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-08-28 | — | — | EP | disclosed |
| EP-1234821-A1 | 1,3,4-OXADIAZOLINE DERIVATIVES AND DRUGS CONTAINING THESE DERIVATIVES AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-08-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210401797-A1 | Taxane Analogs for the Treatment of Brain Cancer | TUBB, TUBB2A, TUBB1 | CA1 2698/4885CA2 3583/4885CA7 2691/4885 |
| US-20030166574-A1 | 1,3,4-Oxadiazoline derivatives and drugs containing these derivatives as active ingredient | ACIN1, CASP7, SERPINE1 | CA1 501/4885CA2 1618/4885CA7 1281/4885 |
| US-20180105535-A1 | Biologically Active Taxane Analogs and Methods of Treatment by Oral Administration | DPYD, DUT, TOP2B | CA1 2682/4885CA2 4099/4885CA7 1437/4885 |
| US-11220512-B2 | Biologically active taxane analogs and methods of treatment by oral administration | DPYD, DUT, TOP2B | CA1 2682/4885CA2 4099/4885CA7 1437/4885 |
| US-20070004642-A1 | Oxadiazole derivatives and drugs containing these derivatives as the active ingredient | ACIN1, CYCS, CASP7 | CA1 538/4885CA2 1853/4885CA7 1781/4885 |
| US-10450323-B2 | Biologically active taxane analogs and methods of treatment by oral administration | DPYD, DUT, TOP2B | CA1 2682/4885CA2 4099/4885CA7 1437/4885 |
| US-20200347076-A1 | Biologically Active Taxane Analogs and Methods of Treatment by Oral Administration | DPYD, DUT, TOP2B | CA1 2682/4885CA2 4099/4885CA7 1437/4885 |
| US-20060111303-A1 | Diketohydrazine derivative compounds and drugs contaiing the compounds as the active ingredient | SERPINB1, CTSZ, SERPINE1 | CA1 326/4885CA2 784/4885CA7 914/4885 |
| US-11786504-B2 | Taxane analogs for the treatment of brain cancer | TUBB, TUBB2A, TUBB1 | CA1 2698/4885CA2 3583/4885CA7 2691/4885 |
| US-20030166573-A1 | Such as (2S)-N-((2S)-4-methyl-1-(5-(1-methylethylthio)1,3,4-oxadiazol-2-yl)-1-oxo-2 -pentyl)-2-benzyloxycarbonylamino-4-methylpentanamide for inhibition of cysteine proteases; antiinflammatory agents | ACIN1, CASP7, ASNS | CA1 739/4885CA2 2018/4885CA7 2347/4885 |
| US-10745408-B2 | Biologically active taxane analogs and methods of treatment by oral administration | DPYD, DUT, TOP2B | CA1 2682/4885CA2 4099/4885CA7 1437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.